Skip to content
SPC Logo

MOVIPREP Orange, powder for oral solution

Last Updated on eMC 22-Aug-2017 View document  | Norgine Limited Contact details

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC.  For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 22-Aug-2017 and displayed until Current

Reasons for adding or updating:

  • Change to section 4.2 - Posology and method of administration
  • Change to section 10 - Date of revision of the text

Date of revision of text on the SPC: 10-Aug-2017

Legal Category:P

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:



Section 4.2 posology update to include the procedure conducted when you are put under general anaesthesia and without general anaesthesia

Updated on 07-Jul-2016 and displayed until 22-Aug-2017

Reasons for adding or updating:

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.3 - Preclinical safety data
  • Change to section 10 - Date of revision of the text

Date of revision of text on the SPC: 29-Apr-2016

Legal Category:P

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:



Section 2 – minor change to the sentence regarding list of excipients.

 

Section 4.2 – addition of the word ‘clinical’ before procedure throughout various paragraphs.

 

Section 4.7 – minor amends to the wording of the sentence regarding ability to use machinery.

 

Section 4.8 – minor amendments to the description of the frequencies.

 

Section 5.3 – update to the information on reproductive toxicology studies.

Updated on 14-Aug-2015 and displayed until 07-Jul-2016

Reasons for adding or updating:

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Fertility, pregnancy and lactation
  • Change to section 4.8 - Undesirable effects - how to report a side effect
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Improved presentation of SPC

Date of revision of text on the SPC: 01-Jul-2015

Legal Category:P

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:



For the SMPC the following changes have been made.

 

 

Section 2          -addition of the title – ‘Excipients with known affect’

 

Section 4.2       -an additional dosing option has been added to include the option of ‘two litres in the morning of the clinical procedure’. Further information around the dosing has been added.

                     -information around the method of administration has been added.

 

Section 4.3       -statement about the hypersensitivity to excipients has been aligned with QRD wording.

 

Section 4.4       -addition of the sentence ‘ The fluid content of Moviprep when re-constituted with water does not replace regular fluid intake and adequate fluid intake must be maintained’

                     -addition of statements regarding those at risk of arrhythmia

                     -addition of statements regarding the content of absorbable sodium, potassium and aspartame in relation to at risk patients.

 

Section 4.6       -general information added about use in pregnancy and breastfeeding.

 

Section 4.8       -the addition of the adverse event  arrhythmia, to cardiac disorders

                     -the order of some adverse events has been amended

                     -addition of the statement  ‘Dehydration may occur as a result of diarrhoea and/or vomiting.’

                     - addition of information regarding adverse event reporting.

 

Section 6.6       -information added to the precautions for disposal

 

Improved presentation of SPC

                     -the spelling of Sulphate has been changed from Sulphate and Sulfate throughout.

                     -MOVIPREP uppercase text has been changed to lowercase text throughout.

 

Updated on 21-Jan-2013 and displayed until 14-Aug-2015

Reasons for adding or updating:

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Date of revision of text on the SPC: 01-Jun-2012

Legal Category:P

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:

Section 2 (Qualitative and quantitative composition), glucose has been replaced with dextrose.

Section 4.8 (undesirable effects), the frequency of adverse reactions have been removed from the begining of the section. Pruritus was added, and oedema was replaced with angioedema; 'population of 591 patients' was changed to 'population of 825 patients'.

The following information was added:

' Addotionally, adverse events reported in postmarketing are included.

The frequency of adverse reactions to MOVIPREP is defined using the following convention:

Very common ≥ 1/10 (≥10%)
Common ≥ 1/100, < 1/10 (≥ 1%, < 10%)
Uncommon ≥1/1000, < 1/100 (≥ 0.1%, <1%)
Rare ≥ 1/10,000, < 1/1,000 (≥ 0.01%, < 0.1%)
Very rare < 1/10,000 (< 0.01%)
Not known (cannot be estimated from the available data)'

The table has been replaced with an updated one (new inforamtion).

Section 5.1 (Pharmacodynamic properties), 'Osmotically acting laxative'  and 'ATC code:' (before A06A D) has been added.

The following information has been added: 'The oral administration of macrogol-based electrolyte solutions causes moderate diarrhoea and results in rapid emptying of the colon.'

The following: 'The electrolytes present in the formulation as well as the supplementary clear liquid intake ensure that there are no clinically significant variations of sodium, potassium or water, and thus no dehydration risk.'

has been updated to: 'The electrolytes present in the formulation and as well as the supplementary clear liquid intake are included to prevent ensure that there are no clinically significant variations of sodium, potassium or water, and thus reduce no dehydration risk.'


Section 5.3 (Preclinical safety data), the following has been added: 'No studies have been carried out on the genotoxicity, carcinogenicity or toxic effect on reproduction with this product.'

Section 7 ( MA Holder), the address has not changed but has been updated.

Section 10 (Date of revision of the text), 06/08/2010 changed to 1 June 2012

Updated on 20-Oct-2010 and displayed until 21-Jan-2013

Reasons for adding or updating:

  • Correction of spelling/typing errors

Date of revision of text on the SPC: 06-Aug-2010

Legal Category:P

Black Triangle (CHM): NO

Updated on 23-Aug-2010 and displayed until 20-Oct-2010

Reasons for adding or updating:

  • New SPC for new product

Legal Category:P

Black Triangle (CHM): NO

Company contact details

Norgine Limited

Company image
Address

Norgine House, Widewater Place, Moorhall Road, Harefield, Middlesex, UB9 6NS

Fax

+44 (0)1895 825 865

Medical Information e-mail
Telephone

+44 (0)1895 826 600

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

ascorbic acid, macrogol 3350, potassium chloride, sodium ascorbate, sodium chloride, sodium sulfate, anhydrous

Legal categories

P - Pharmacy

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue